You cap the upside when you partner. Ya'll are so excited about ISIS several partnership deals but ISIS market cap isn't much higher than SRPT. ISIS has several partnership deals and SRPT has none. You do the math.
The big upside is remaining independent, not giving the upside away to big pharma.
Not true - by partnering ISIS is allowed to stick at what they are good at, R&D. Their partner finances the efforts, and ISIS receives royalties. This allows them to remain small and maximize their efforts in a single direction.
Gaining approval and having the wherewithal to roll out multiple products in multiple disciplines would be highly questioned by the analytic community. As it stands, ISIS has its best chances for approval in multiple disease indications. Having big pharma as a partner ACKNOWLEDGES the data and its implications. Perhaps those with Big Pharma backing have this backing BECAUSE THEIR DATA IS VALID versus those who have to go it alone.... I will patiently await the day SRPT turns down big pharma's advances...because they may never come, and one must question why. ?